DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch [Yahoo! Finance]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
the safety and efficacy of its lead product candidate, DM199, to treat acute ischemic stroke (AIS). The company's shares gained 9.7% on Apr 17, following the encouraging news. DM199 is DiaMedica's recombinant (synthetic) form of human tissue kallikrein-1, which will be developed in the pivotal phase II/III ReMEDy2 study for AIS patients. The investigational candidate's novel mechanism of action aims at enhancing collateral blood flow in the brain tissues affected by the stroke. In 2022, the FDA placed a clinical hold on DiaMedica's ReMEDy2 study of DM199 based on three reports of serious treatment-related adverse events. It was observed that those three AIS patients experienced clinically significant transient hypotension (low blood pressure), shortly after initiation of the intravenous (IV) dose of DM199. Additionally, the blood pressure levels of the three patients recovered back to their baseline blood pressure within minutes after the IV infusion was stopped. Eventually, t
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeBusiness Wire
- DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
DMAC
Earnings
- 11/13/23 - Beat
DMAC
Sec Filings
- 4/10/24 - Form 8-K
- 4/10/24 - Form EFFECT
- 4/4/24 - Form ARS
- DMAC's page on the SEC website